Dalbavancin

Therapeutic

Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms:

Structural features

SMILES

CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)NC(C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O

Sequence

-

Molar mass

1816.71 g/mol

Constitutional members:

N.A.

Natural amino acids

N.A.

D-Amino acids

N.A.

N-terminus

CH3

C-terminus

N.A.

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

C-O-C; C-C

Lipidation

yes

Glycosylation

yes - 2 sugars

Route of administration

IV

Terminal half-life

346 hours

Protein binding

0.93

Absorption and Bioavailability

Due to its poor oral bioavailability, it is available only in an intravenous formulation

References